Ray Dalio Tg Therapeutics, Inc. Transaction History
Bridgewater Associates, LP
- $23.8 Billion
- Q3 2025
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 342,149 shares of TGTX stock, worth $10.6 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
342,149Holding current value
$10.6 Million% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding TGTX
# of Institutions
394Shares Held
90.6MCall Options Held
1.79MPut Options Held
1.9M-
Vanguard Group Inc Valley Forge, PA15.5MShares$481 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$353 Million0.0% of portfolio
-
State Street Corp Boston, MA8.1MShares$251 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY4.64MShares$144 Million0.13% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.84MShares$119 Million8.45% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.5B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...